Medical device company Integra LifeSciences (NASDAQ: IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates.

Is now the time to buy IART? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursement pressures in certain product lines and challenging year-over-year comparisons, especially in the tissue reconstruction segment. CEO Stuart Essig highlighted that while the company achieved important operational milestones—including the relaunch of key products and improved supply reliability—margin compression stemmed from a mix of increased interest expenses and product mix shifts. CFO Lea Daniels Knight acknowledged that, “the quarter’s outperformance in adjusted EPS was largely driven by operational execution and favorable tariff dynamics,” but reiterated that the company is operating in a complex environment marked by reimbursement and competitive challenges.

Looking forward, Integra LifeSciences’ guidance reflects cautious optimism as management focuses on execution and strategic product launches to drive growth. The company’s outlook is shaped by expectations for improved supply reliability, seasonal demand, and the phased relaunch of SurgiMend in the fourth quarter, with Essig emphasizing, “our broader objective is to expand the opportunity for both SurgiMend and DuraSorb through our dual PMA strategy in implant-based breast reconstruction.” However, the company also signaled that higher interest expenses and reimbursement headwinds will temper near-term earnings, even as ongoing cost savings initiatives are expected to offset these pressures. Management’s approach centers on disciplined execution, operational efficiency, and a gradual recovery in key product lines.

Key Insights from Management’s Remarks

Management cited improved operational execution, product relaunch momentum, and a realigned commercial structure as central themes affecting both flat revenue performance and evolving profitability in the quarter.

• Operational execution improvements: The company emphasized enhanced coordination across divisions and a streamlined operating model, which delivered cost savings and improved supply reliability. Essig stated these changes helped build a stronger foundation for future growth, even as overall revenue remained flat year over year.

• Tissue reconstruction volatility: Management pointed out that year-over-year declines in tissue reconstruction were primarily driven by tough prior-year comparisons and ongoing competition within the segment. While Integra Skin and MicroMatrix faced pressure, PriMatrix’s relaunch showed sequential growth and customer reengagement, recovering to more than 50% of pre-recall revenue levels within nine months.

• Specialty surgery resilience: The neurosurgery portfolio, including Certas Plus and CUSA, delivered modest organic growth as supply chain issues eased. The company’s leadership highlighted that established relationships with hospitals and group purchasing organizations (GPOs) remain a competitive advantage, particularly in neurosurgery and instruments.

• ENT segment pressures and strategy: Ear, nose, and throat (ENT) product sales declined, with MicroFrance instrument growth offset by reimbursement challenges impacting sinus balloons. Management sees long-term growth in ENT coming from innovation in navigated systems and Eustachian tube products, rather than current core offerings.

• Leadership and organizational changes: The promotion of a new chief commercial officer and new division heads aims to reinforce accountability, accelerate decision-making, and leverage cross-division commercial synergies. Management confirmed no broad sales force restructuring, focusing instead on expanding enterprise contracting and deepening hospital engagement.

Drivers of Future Performance

Looking ahead, Integra LifeSciences’ outlook is supported by supply improvements, new product launches, and ongoing cost discipline, but faces headwinds from higher interest rates and shifting reimbursement dynamics.

• Product relaunches and approvals: The phased relaunch of SurgiMend in the fourth quarter, along with future regulatory approvals for SurgiMend and DuraSorb in breast reconstruction, are expected to drive incremental growth starting in 2027. Management does not anticipate meaningful SurgiMend revenue this year, but expects share recapture and broader portfolio strength to materialize over multiple quarters.

• Cost savings and operational efficiency: Ongoing transformation initiatives are projected to yield $25–30 million in 2026 cost savings, with an additional $10–15 million annualized benefit in 2027. These savings are targeted to offset increased interest expenses and to support margin improvement as remediation and transformation costs decline.

• Reimbursement and competitive landscape: The company faces continued reimbursement headwinds in core segments, particularly in tissue reconstruction and ENT. Management’s strategy to navigate these challenges includes portfolio diversification, deepening enterprise relationships, and emphasizing clinical evidence to defend market share.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will closely monitor (1) the phased commercial relaunch of SurgiMend and early demand signals from both legacy and new customers, (2) the pace and sustainability of cost savings from the current transformation initiatives and their effect on margins, and (3) signs of supply chain stability and recovery in key product lines, especially in tissue reconstruction and neurosurgery. The completion of regulatory milestones for SurgiMend and DuraSorb will also be critical markers for future growth potential.

Integra LifeSciences currently trades at $16.35, down from $19.76 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.